SCHEMBL23930587

SCHEMBL23930587

N#CN=C(S)Nc1ccc(F)cc1.[KH]

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
TP53 P04637 1/20 0.40
MAPK10 P53779 1/20 0.40
LMNA P02545 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 2/20 0.38
RAB9A P51151 2/20 0.38
IDO1 P14902 1/20 0.38
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TGM2 P21980 1/20 0.37
TAAR1 Q96RJ0 1/20 0.36
PTPN1 P18031 1/20 0.36
NPC1 O15118 1/20 0.36
NOX1 Q9Y5S8 1/20 0.36
P2RX7 Q99572 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28964283 0.98 ALDH1A1 (0.41) ALDH1A1TP53MAPK10LMNAMEN1
SCHEMBL17238089 0.96 ALDH1A1 (0.40) ALDH1A1TP53MAPK10LMNAMEN1
SCHEMBL5949813 0.80 SIGMAR1 (0.41) TP53IDO1
SCHEMBL5949807 0.80 SIGMAR1 (0.41) TP53IDO1
SCHEMBL19673833 0.79 ALDH1A1 (0.43) ALDH1A1TP53LMNAMEN1KMT2A
SCHEMBL16014418 0.79 CNR1 (0.39) ALDH1A1TP53MEN1KMT2ARAB9A
SCHEMBL17238111 0.79 TDP1 (0.41) LMNAMEN1KMT2ARAB9AMAPT
SCHEMBL17238096 0.79 MAPT (0.45) ALDH1A1TP53LMNAMEN1KMT2A
SCHEMBL21313128 0.78 ALDH1A1 (0.42) ALDH1A1TP53LMNAMEN1KMT2A
SCHEMBL17238103 0.77 MEN1 (0.46) ALDH1A1MAPK10LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 EP disclosed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG ALDH1A1 3965/4885TP53 855/4885MAPK10 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.